ASC Therapeutics
We are dedicated to discovering, developing and delivering cures for intractable and rare diseases.
We are passionate about helping patients lead more hopeful, healthier and happier lives
ASC Therapeutics is
"HERE TO CURE".
ASC Therapeutics is a fully incorporated biopharmaceutical company focusing on the development of curative therapeutic products that are enabled by our proprietary gene editing platform, TARGATT™ and other gene editing technologies developed after 12 years of R&D at Applied Stem Cells, Inc.
The company’s therapeutic development pipeline includes several preclinical stage programs in gene and cell therapy progressing into clinical stage in 2022 focusing on several blood disorders.
VISION
To provide cures to patients with intractable diseases through innovative technologies and therapeutics that are both groundbreaking and safe.
FOCUS
ASC Therapeutics strives to discover, develop, and deliver gene and cell treatments to cure intractable and emerging diseases.
DNA
Our diverse team has decades of experience in cutting edge stem-cell and gene therapy research. Together we strive to be innovators to provide platforms to revolutionize the way diseases are treated.
Our Pipeline
Discovery
Preclinical
Phase 1/2a
Phase 2b
GVHD
Cell Therapy/phase 2b
Hemophilia A
Gene Therapy
Hemophilia A
Gene Editing
Hemophilia B
Gene Editing
β-Thalassemia
Gene Editing
Undisclosed
Gene editing, Gene/Cell Therapy
Dicscovery
Preclinical
Phase 1/2a
Phase 2b
Hemophilia A
Gene Therapy
Hemophilia A
Gene Editing
Hemophilia B
Gene Editing
β-Thalassemia
Gene Editing
GVHD
Cell Therapy/phase 2B
Undisclosed
Gene editing, Gene/Cell Therapy
Our current pipeline is focused on blood diseases. We are devoted to discovering, developing and delivering cures for intractable diseases using gene and cell therapies.
Not only do we have experienced teams for discovery research, CMC, pre-clinical and clinical development, we also collaborate with leading academic and industry partners around the world to advance and expand our product pipeline. Building upon our deep knowledge in stem cell, gene therapy and genome editing technology, we are devoted to discovering, developing and delivering cures for intractable diseases.
Our Team
Executive Team
Ruhong Jiang, PhD
Co-founder, President and CEO
Gary Potter
Senior VP, Global Operations
Zoya Gluzman-Poltorak, PhD, MBA
VP, Therapeutic Development
Weicheng Wu, PhD, RAC
VP, Global Regulatory Affairs
Terry Brown
Senior Director, Quality
Jeremy Watts
Director, Corporate Program Management
Hemophilia Advisory Board
Mark A. Kay, MD, Ph.D
Dennis Farrey Family Professor in Department of Pediatrics, Professor of Genetics, Stanford University
Steven Pipe, MD, PhD
Professor of Pediatrics and Pathology, Medical Director of the Pediatric Hemophilia and Coagulation Disorders Program at the University of Michigan
Cell Therapy Advisory Board
Olle Ringdén, MD, PhD
Professor of Transplantation Immunology, Karolinska Institute
Behnam Sadeghi, MD, PhD
Head of translational cell therapy Research group, Karolinska Institute
John E. Wagner, MD
Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota
Robert Negrin, MD
Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.
Robert Negrin, MD
Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University.
Olle Ringdén, MD, PhD
Professor of Transplantation Immunology, Karolinska Institute
Behnam Sadeghi, MD, PhD
Head of translational cell therapy Research group, Karolinska Institute
John E. Wagner, MD
Director of the Institute for Cell, Gene and Immunotherapy and Member of the BMT Program, University of Minnesota
Maple Syrup Urine Disease Advisory Board
Guangping Gao, PhD
AAV gene therapy pioneer
Kevin Strauss, MD
PI of Zolgensma gene therapy
Guangping Gao, PhD
Biomedical Research, University of Massachusetts Medical School
Guangping Gao, PhD
AAV gene therapy pioneer
Kevin Strauss, MD
PI of Zolgensma gene therapy
Dan Wang, PhD
Biomedical Research, University of Massachusetts Medical School
NEWS & BLOG
Latest News & Blogs Posts
Investors
Hermed Capital
Hermed Capital Fund (the “Fund”) is a private equity fund that will invest primarily in healthcare industry around the world.
Fosun International
Fosun International Limited is a technology-driven consumer group that has been listed on the main board of the Hong Kong Stock Exchange (00656.HK) since 2007.
Ping An Group
Ping An of China is devoted to becoming a world-leading personal financial services provider.
Simcere
Simcere Pharmaceutical Group is China's leading R&D-driven pharmaceutical company. It has been ranked amongst the top 100 pharmaceutical companies in China and in the top 10 of the most innovative pharmaceutical companies in China for several consecutive years. Simcere was the first Chinese biological and chemical pharmaceutical company to be listed on the New York Stock Exchange.
Advantech Capital
Launched in January 2016 by Mr. Jianming Yu, Advantech Capital is a private equity fund, focused on innovation-driven growth capital in China.
Partners
Stanford University
Stanford University, officially Leland Stanford Junior University, is a private research university in Stanford, California. Stanford is known for its academic achievements, wealth, close proximity to Silicon Valley, and selectivity; it ranks as one of the world's top universities.
Emory University
Emory University, a top-ranked private institution recognized internationally for its outstanding liberal arts colleges, graduate and professional schools, and one of the world's leading healthcare systems, is located on a beautiful campus in Atlanta, Georgia's historic Druid Hills neighborhood.
Shantou University
Shantou University, a key comprehensive university under the provincial Project 211 program in Guangdong, was founded in 1981 with the approval of the State Council. It is the only public university that receives funding from the Li Ka Shing Foundation.
Peking University Shenzhen Hospital
Peking University Shenzhen Hospital, opened in 1999, is a modern general hospital based in Shenzhen with an investment of RMB 4.5 billion. Under the cooperation of Shenzhen municipal government and Peking University, the hospital was absorbed into the management system of Peking University Hospital in the year 2001.
ASC Therapeutics
Company Timeline
2008
Stem cell and gene editing platforms for research
2018
IND enabling stage for two programs
2020
Applied stem cell spinoff in
June 2020 Received two
FDA’s orphan drug
2022
FDA's Fast Track Designation and
EMA's Orphan Drug Designation for ASC618
$19m
$80m
Gene and cell therapeutic division
2016
ASCT incorporated in
July 2019
2019
IND Clearance for ASC618
2021
$5m
$19m
$44m
$55m
$65m
$80m
2008
Stem cell and gene editing platforms for research, bio-production.
2016
Gene and cell therapeutic division
2018
IND enabling stage for two programs
2019
ASCT incorporated in July 2019
2020
Applied stem cell spinoff in June 2020 received two FDA’s orphan drug designation
2021
IND Clearance for ASC618
2022
FDA's Fast Track Designation and EMA's Orphan Drug Designation for ASC618